203 related articles for article (PubMed ID: 15210523)
1. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
[TBL] [Abstract][Full Text] [Related]
2. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
Camicioli RM; Bouchard TP; Somerville MJ
Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
[TBL] [Abstract][Full Text] [Related]
5. Clinical course in Parkinson's disease with elevated homocysteine.
O'Suilleabhain PE; Oberle R; Bartis C; Dewey RB; Bottiglieri T; Diaz-Arrastia R
Parkinsonism Relat Disord; 2006 Mar; 12(2):103-7. PubMed ID: 16368256
[TBL] [Abstract][Full Text] [Related]
6. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
7. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
8. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Irizarry MC; Gurol ME; Raju S; Diaz-Arrastia R; Locascio JJ; Tennis M; Hyman BT; Growdon JH; Greenberg SM; Bottiglieri T
Neurology; 2005 Nov; 65(9):1402-8. PubMed ID: 16275827
[TBL] [Abstract][Full Text] [Related]
9. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
11. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results.
Dittmann S; Seemüller F; Schwarz MJ; Kleindienst N; Stampfer R; Zach J; Born C; Bernhard B; Fast K; Grunze H; Engel RR; Severus E
Bipolar Disord; 2007; 9(1-2):63-70. PubMed ID: 17391351
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life.
Almeida OP; Flicker L; Lautenschlager NT; Leedman P; Vasikaran S; van Bockxmeer FM
Neurobiol Aging; 2005 Feb; 26(2):251-7. PubMed ID: 15582752
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.
Aarsland D; Brønnick K; Larsen JP; Tysnes OB; Alves G;
Neurology; 2009 Mar; 72(13):1121-6. PubMed ID: 19020293
[TBL] [Abstract][Full Text] [Related]
16. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine and cognitive impairment in Parkinson's disease].
Martín-Fernández JJ; Carles-Díes R; Cañizares F; Parra S; Avilés F; Villegas I; Morsi-Hassan O; Fernández-Barreiro A; Herrero MT
Rev Neurol; 2010 Feb 1-15; 50(3):145-51. PubMed ID: 20146187
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis.
Zoccolella S; Simone IL; Lamberti P; Samarelli V; Tortelli R; Serlenga L; Logroscino G
Neurology; 2008 Jan; 70(3):222-5. PubMed ID: 18195267
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
[TBL] [Abstract][Full Text] [Related]
20. The rate of cognitive decline in Parkinson disease.
Aarsland D; Andersen K; Larsen JP; Perry R; Wentzel-Larsen T; Lolk A; Kragh-Sørensen P
Arch Neurol; 2004 Dec; 61(12):1906-11. PubMed ID: 15596611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
